Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo during different pathologies

Laboratory of Cellular and Molecular Immunology, Department of Molecular and Cellular Interactions, Vlaams Interuniversitair Instituut voor Biotechnologie, Vrije Universiteit Brussel, Belgium.
Blood (Impact Factor: 10.45). 08/2006; 108(2):575-83. DOI: 10.1182/blood-2005-04-1485
Source: PubMed


Compared with type I cytokine-associated myeloid (M1) cells, the molecular repertoire and mechanisms underlying functional properties of type II cytokine-associated myeloid (M2) cells are poorly characterized. Moreover, most studies have been limited to in vitro-elicited M2 cells. Here, comparative gene expression profiling of M1 and M2 cells, elicited in murine models of parasitic infections and cancer, yielded a common signature for in vivo-induced M2 populations independent of disease model, mouse strain, and organ source of cells. Some of these genes, such as cadherin-1, selenoprotein P, platelet-activating factor acetylhydrolase, and prosaposin, had not been documented as associated with M2. Overall, the common signature genes provide a molecular basis for a number of documented or suggested properties of M2, including immunomodulation, down-regulation of inflammation, protection against oxidative damage, high capacity for phagocytosis, and tissue repair. Interestingly, several common M2 signature genes encode membrane-associated markers that could be useful for the identification and isolation of M2. Some of these genes were not induced by IL-4/IL-13 or IL-10 under various in vitro settings and thus were missed in approaches based on in vitro-activated cells, validating our choice of in vivo models for expression profiling of myeloid cells.

Download full-text


Available from: Jo Van Ginderachter,
  • Source
    • "Indeed, M2-macrophages differentiate from monocytes in response to specific growth factors released by both malignant and stromal tumor compartments, including CCL2, M-CSF, vascular endothelial growth factor (VEGF) and CXCL12 (also known as SDF1) [2], [15], [16]. Macrophage polarization is also regulated by post-stimulations such as the M2a stimulants IL-4 and IL-13, M2b stimulants including immune complexes/TLR ligands, and IL-10 and glucocorticoids polarize macrophages into the M2c subtype [13], [17]. In general, the hallmarks of M2-macrophages are production of IL-10high, IL-12low, IL-1RAhigh, IL-1decoyRhigh, CCL17high, and CCL22high. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor cells are often associated with abundant macrophages that resemble the alternatively activated M2 subset. Tumor-associated macrophages (TAMs) inhibit anti-tumor immune responses and promote metastasis. Cyclooxygenase-2 (COX-2) inhibition is known to prevent breast cancer metastasis. This study hypothesized that COX-2 inhibition affects TAM characteristics potentially relevant to tumor cell metastasis. We found that the specific COX-2 inhibitor, etodolac, inhibited human M2 macrophage differentiation, as determined by decreased CD14 and CD163 expressions and increased TNFα production. Several key metastasis-related mediators, such as vascular endothelial growth factor-A, vascular endothelial growth factor-C, and matrix metalloproteinase-9, were inhibited in the presence of etodolac as compared to untreated M2 macrophages. Murine bone marrow derived M2 macrophages also showed enhanced surface MHCII IA/IE and CD80, CD86 expressions together with enhanced TNFα expressions with etodolac treatment during differentiation. Using a BALB/c breast cancer model, we found that etodolac significantly reduced lung metastasis, possibly due to macrophages expressing increased IA/IE and TNFα, but decreased M2 macrophage-related genes expressions (Ym1, TGFβ). In conclusion, COX-2 inhibition caused loss of the M2 macrophage characteristics of TAMs and may assist prevention of breast cancer metastasis.
    PLoS ONE 05/2013; 8(5):e63451. DOI:10.1371/journal.pone.0063451 · 3.23 Impact Factor
  • Source
    • "MHCII high CD206 -TAMs were more M1-oriented and less able to penetrate hypoxic areas while MHCII low CD206 + TAMs were more M2-oriented, able to penetrate hypoxic areas, promote angiogenesis, and even produce IL-10 in human hepatocellular cancer [54] [68]. Differences in TAM populations have also been apparent on the level of gene expression, with an invasive MCSF-R + dextran -TAM population that co-migrates with cancer cells showing marked divergence compared to that of MCSF- R + dextran + TAMs [32] [69]. These differences were not appreciated before assortment along dextran-ingestion but once this filter was applied , all genes of a consensus signature for type II cytokine-associated M2-type macrophages were expressed at a lower level in dextran -TAMs compared to dextran + TAMs [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrophages are the dominant leukocyte population found in the tumor microenvironment. Accumulating evidence suggests that these tumor-associated macrophages (TAMs) actively promote all aspects of tumor initiation, growth, and development. However, TAMs are not a single uniform population; instead, they are composed of multiple distinct pro- and anti-tumoral subpopulations with overlapping features depending on a variety of external factors. Defining and differentiating these subsets remains a challenging work-in-progress. These difficulties are apparent in prognostic studies in lung cancer that initially demonstrated conflicting evidence regarding the significance of TAMs but which have more recently clarified and confirmed the clinical importance of these subsets through improved phenotypic capabilities. Thus, these cells represent potential targets for cancer therapeutic initiatives through translational approaches. In this review, we summarize the current understanding of how the tumor microenvironment takes advantage of macrophage plasticity to mold an immunosuppressive population, the phenotypic heterogeneity of TAMs, and their link to prognosis in human lung cancer.
    American Journal of Translational Research 11/2012; 4(4):376-89. · 3.40 Impact Factor
  • Source
    • "For example, the so-called alternatively activated macrophages (or M2 macrophages) have been associated with limiting collateral tissue damage during excessive infection-associated type 1 inflammation (Raes et al. 2007). As such, mouse and human M2-associated surface markers, such as Macrophage mannose receptor (MMR), Macrophage galactosetype C-type lectins (MGL) and E-cadherin (Ghassabeh et al. 2006; Raes et al. 2005; Stein et al. 1992; Van den Bossche et al. 2009) may represent useful biomarkers for using myeloid cells and the activation states they acquire in response to various triggers as sensitive in vivo sensors during inflammation and cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In vivo imaging technology holds promise for refined monitoring of inflammation, both in the clinic and in preclinical animal models, with applications including improved diagnosis, prognosis and therapy monitoring. In particular, molecular imaging, aimed at non-invasively studying molecular and cellular processes in intact organisms, can hereby not only provide information about the amount of inflammation, but also on the type of inflammation and on cells and/or receptors involved. Hereto, an important requisite is the availability of the proper biomarkers and specific probes for targeting these biomarkers. In the current review, we focus on a number of markers on inflamed endothelium and infiltrating myeloid cells (including macrophages) as interesting targets for tracking inflammatory reactions and argue that such markers are not only useful in case of inflammatory diseases of infectious or autoimmune origin, but also for monitoring cancer evolution through the associated inflammation. We elaborate on nanobodies as innovative, specific probes to target these inflammation-associated markers for in vivo molecular imaging.
    Immunobiology 07/2012; 217(12). DOI:10.1016/j.imbio.2012.07.009 · 3.04 Impact Factor
Show more